Details of the Drug Combinations

General Information of This Drug (ID: DMT81LZ)

Drug Name
ARN-509   DMT81LZ
Synonyms Arn-509 (AR inhibitor)
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Prostate cancer 2C82.0 Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Everolimus + Arn-509 DCA4W33 Everolimus Prostate Cancer [3]
Relugolix + Arn-509 DCRLSKB Relugolix Metastatic Castration-Resistant Prostate Cancer [4]
ABIRATERONE + Arn-509 DC1MW8P ABIRATERONE Prostatic Neoplasms, Castration-Resistant [5]
Degarelix + Arn-509 DC3H2SN Degarelix Prostate Cancer [6]
Leuprolide + Arn-509 DCJYGIX Leuprolide Prostate Cancer [7]
Enzalutamide + Arn-509 DCGO6BD Enzalutamide Prostate Cancer [8]
Gonadorelin + Arn-509 DCMQMZU Gonadorelin Prostate Cancer [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT01946204) A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02106507) ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
4 ClinicalTrials.gov (NCT04666129) Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
5 ClinicalTrials.gov (NCT03173859) Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
6 ClinicalTrials.gov (NCT03080116) Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
7 ClinicalTrials.gov (NCT02770391) Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
8 ClinicalTrials.gov (NCT04409288) Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
9 ClinicalTrials.gov (NCT03009981) A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer